← Back to Search

Radiation Therapy

Adaptive Radiotherapy for Glioblastoma (UNITED-3 Trial)

N/A
Recruiting
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, anticipated 6-24 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test an adaptive two-phase radiation therapy approach to see if it better controls glioblastoma than standard radiation therapy. It will also monitor survival, side effects and quality of life.

Who is the study for?
This trial is for adults with newly diagnosed glioblastoma or grade 4 astrocytoma. They must have had a biopsy or surgery within the last 12 weeks, good blood counts and organ function, an expected survival of at least 12 weeks, and be in fair to good physical condition. Participants need to understand English for questionnaires and commit to treatment follow-up.
What is being tested?
The study tests an adaptive two-phase radiation therapy (RT) against standard RT in patients with glioblastoma. It aims to see if this new method improves tumor control, survival rates without disease progression, failure patterns, toxicity impact on neurological functions, and life quality.
What are the potential side effects?
While not specified here, typical side effects of radiation therapy may include fatigue, skin reactions at the treatment site like redness or irritation; headaches; nausea; hair loss around treated area; and potential cognitive changes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, anticipated 6-24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, anticipated 6-24 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Changes in neurologic function
Health-related Quality of Life
Rate of toxicity

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Adaptive, two-phase RTExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
674 Previous Clinical Trials
1,565,815 Total Patients Enrolled

Media Library

Adaptive, two-phase RT (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT05720078 — N/A
Brain Cancer Research Study Groups: Adaptive, two-phase RT
Brain Cancer Clinical Trial 2023: Adaptive, two-phase RT Highlights & Side Effects. Trial Name: NCT05720078 — N/A
Adaptive, two-phase RT (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05720078 — N/A
~8 spots leftby Apr 2025